Voss Capital LP Purchases Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX

Voss Capital LP purchased a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 125,000 shares of the company’s stock, valued at approximately $2,626,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Palumbo Wealth Management LLC bought a new stake in Syndax Pharmaceuticals in the 4th quarter valued at $1,079,000. Apis Capital Advisors LLC bought a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter worth about $9,816,000. Torray Investment Partners LLC bought a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth about $2,055,000. SG Americas Securities LLC grew its holdings in shares of Syndax Pharmaceuticals by 184.5% in the 4th quarter. SG Americas Securities LLC now owns 129,227 shares of the company’s stock worth $2,715,000 after purchasing an additional 83,801 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Syndax Pharmaceuticals by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 5,138,617 shares of the company’s stock worth $79,058,000 after purchasing an additional 104,683 shares during the last quarter.

Syndax Pharmaceuticals Stock Up 1.9%

Shares of NASDAQ:SNDX opened at $18.25 on Friday. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.59 and a 12 month high of $25.59. The company’s 50-day moving average price is $21.06 and its two-hundred day moving average price is $21.22. The company has a quick ratio of 5.06, a current ratio of 5.47 and a debt-to-equity ratio of 8.26. The firm has a market cap of $1.62 billion, a P/E ratio of -6.54 and a beta of 0.38.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The firm had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. During the same quarter in the prior year, the firm earned ($0.98) EPS. The company’s revenue was up 224.3% on a year-over-year basis. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -1.66 EPS for the current fiscal year.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 6,847 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $18.99, for a total transaction of $130,024.53. Following the sale, the chief executive officer owned 484,843 shares of the company’s stock, valued at $9,207,168.57. This represents a 1.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Nicholas A.J. Botwood sold 31,235 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $18.14, for a total transaction of $566,602.90. Following the sale, the chief marketing officer directly owned 60,885 shares in the company, valued at approximately $1,104,453.90. This represents a 33.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 73,539 shares of company stock worth $1,336,019. Insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. Stifel Nicolaus set a $45.00 target price on shares of Syndax Pharmaceuticals in a report on Friday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Syndax Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. upped their target price on shares of Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an “overweight” rating in a report on Monday, March 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 target price (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.55.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.